There's never a shortage of losers in the stock market.
Let's take a closer look at five of this past week's biggest sinkers.
|Dec. 9||Weekly Loss||My Watchlist|
Invacare called in sick after the Food and Drug Administration observed violations at Invacare's corporate headquarters and at a wheelchair-manufacturing facility. The FDA is issuing a consent decree that may temporarily shut down some of Invacare's business.
XenoPort slipped after a clinical trial for its experimental Parkinson's disease drug failed to deliver impressive results.
Blyth was snuffed out after the maker of picture frames and scented candles missed Wall Street's targets for the third quarter. Adding insult to injury, Blyth also lowered its cash-flow guidance.
Fusion-io took a spill after announcing a secondary stock offering. Fusion-io is one of this year's best-performing IPOs, so investors shouldn't be surprised by the opportunistic stock sale. However, it's never comforting when a company's CEO is one of the sellers.
Spreadtrum fell sharply early in the week but bounced back after the Chinese maker of low-cost mobile phone chips revealed that it's on track to meet or exceed its current quarter's guidance.
It was a rough week for these five stocks. Let's see if they bounce back.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.